

26 February 2018

NSX Announcement

EXTENSION OF EXCLUSIVE PERIOD WITH UNSW

Further to its announcement on 2 November 2017, Beroni Group Limited (“Beroni Group” or the “Company”) advises that it has signed a letter of extension with Cystemix Pty Limited (“Cystemix”) to extend the exclusive period by one month to 31 March 2018, in order to complete assessment of information and due diligence on Cystemix and GSAO prior to it making a decision to invest in Cystemix. The investment (if any) is to fund the necessary clinical trials and commercialisation of GSAO. The terms of investment are to be negotiated by the parties during the exclusive period.

Cystemix is an associated entity of the University of New South Wales, specialising in managing the scientific research and commercialising the development of an anti-cancer drug called GSAO. The Company will continue to inform shareholders of the progress of this potential investment into Cystemix.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Non-Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group’s currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.